High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system

Area of Science:

• Virology
• Molecular Biology
• Clinical Diagnostics

Background:

• Quantitative nucleic acid assays are crucial for monitoring viral infections and treatment response.
• Existing methods for hepatitis B virus (HBV) DNA detection have limitations in sensitivity and reproducibility.

Purpose of the Study:

• To develop and validate a highly sensitive and reproducible quantitative assay for detecting hepatitis B virus (HBV) DNA.
• To compare the performance of the new assay against the current standard branched-chain DNA (bDNA) assay.

Main Methods:

• Development of a quantitative assay using real-time fluorescent-probe polymerase chain reaction (PCR) (TaqMan).
• Testing of serum samples with known HBV DNA levels, ranging from 10 to 10^9 copies/mL.
• Comparison of TaqMan PCR results with bDNA assay results on 157 clinical samples.

Main Results:

• The TaqMan PCR assay demonstrated high sensitivity, accurately detecting HBV DNA from 10 to 10^9 copies/mL.
• Significantly more samples were positive by TaqMan PCR (119/157) compared to bDNA (55/157) (P <.001).
• The assay detected low-level HBV DNA (below 3.75 x 10^5 copies) more effectively than bDNA and showed high concordance with serologic markers.

Conclusions:

• The developed TaqMan PCR assay is highly sensitive, reproducible, and automated for HBV DNA quantitation.
• This assay offers superior performance over the bDNA method for detecting and quantifying HBV DNA.
• The TaqMan assay is a valuable tool for accurately assessing viral replication levels in patients with HBV infection.